2013
DOI: 10.1517/14656566.2013.783568
|View full text |Cite
|
Sign up to set email alerts
|

Valdecoxib: the rise and fall of a COX-2 inhibitor

Abstract: Introduction: Valdecoxib is a cyclooxygenase 2 (COX-2) selective anti -inflammatory drug. It is associated with a reduced incidence of gastrointestinal complications and is potentially useful for patients with rheumatological diseases requiring longer term anti-inflammatory treatment.Areas covered: Due to a perceived increased risk of thrombotic events, particularly cardiovascular hazards and reports of unpredictable, potentially life threatening skin reactions, valdecoxib has been voluntarily withdrawn from t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
23
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 44 publications
(24 citation statements)
references
References 74 publications
1
23
0
Order By: Relevance
“…Indeed, both non-steroidal anti-inflammatory drugs (NSAIDs) and agents that selectively target COX2 (i.e., celecoxib, rofecoxib, valdecoxib) have been developed [24-26]. However, some COX2 inhibitors produce serious side effects such as gastrointestinal, cardiovascular, liver and kidney complications [27-29], resulting in their voluntary withdrawal from the market in some cases [30,31]. Therefore, exploiting α3β1 as a therapeutic target to down-regulate COX2 gene expression might circumvent certain side effects that have been associated with direct inhibitors of COX2.…”
Section: Introductionmentioning
confidence: 99%
“…Indeed, both non-steroidal anti-inflammatory drugs (NSAIDs) and agents that selectively target COX2 (i.e., celecoxib, rofecoxib, valdecoxib) have been developed [24-26]. However, some COX2 inhibitors produce serious side effects such as gastrointestinal, cardiovascular, liver and kidney complications [27-29], resulting in their voluntary withdrawal from the market in some cases [30,31]. Therefore, exploiting α3β1 as a therapeutic target to down-regulate COX2 gene expression might circumvent certain side effects that have been associated with direct inhibitors of COX2.…”
Section: Introductionmentioning
confidence: 99%
“…Hence, more detailed analysis of docking poses and binding mechanisms was performed for the other studied COX isoform: COX-2. Diclofenac, indomethacin, celecoxib, and valdecoxib [46,47] were used as positive controls for COX-2 inhibition. The average binding energy predicted for decoys and known ligands into the COX-2 was −7.6 and −9.3 kcal/mol, respectively (Table 2).…”
Section: Resultsmentioning
confidence: 99%
“…This so-called NSAID enteropathy continues to be greatly underrecognized and is subclinical in the vast majority of cases, and when there are symptoms (including iron-deficiency anemia, occult blood, diarrhea, hypoalbuminemia, and malabsorption), these are largely nonspecific. Unlike for NSAID gastropathy, there are no proven-effective preventive therapies [22,37,38].…”
Section: Gastrointestinal Injury Induced By Acetylsalicylic Acid Nonsmentioning
confidence: 99%